Incidence and survival of choroid plexus tumors in the United States.

IF 2.4 Q2 CLINICAL NEUROLOGY
Kailey Takaoka, Gino Cioffi, Kristin A Waite, Jonathan L Finlay, Daniel Landi, Kaitlyn Greppin, Carol Kruchko, Quinn T Ostrom, Jill S Barnholtz-Sloan
{"title":"Incidence and survival of choroid plexus tumors in the United States.","authors":"Kailey Takaoka,&nbsp;Gino Cioffi,&nbsp;Kristin A Waite,&nbsp;Jonathan L Finlay,&nbsp;Daniel Landi,&nbsp;Kaitlyn Greppin,&nbsp;Carol Kruchko,&nbsp;Quinn T Ostrom,&nbsp;Jill S Barnholtz-Sloan","doi":"10.1093/nop/npac062","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>There are limited data available on incidence and survival of patients with choroid plexus tumors (CPT). This study provides the most current epidemiological analysis of choroid plexus tumors from 2004 to 2017 in the United States.</p><p><strong>Methods: </strong>Data on 2013 patients with CPT were acquired from the Central Brain Tumor Registry of the United States in collaboration with the Centers for Disease Control and Prevention (CDC) and the National Cancer Institute, from 2004 to 2017. CPT cases were classified by the following pathological subtypes: choroid plexus papilloma (CPP), atypical choroid plexus papilloma (aCPP), and choroid plexus carcinoma (CPC). Frequencies and age-adjusted incidence rates (AAIR) per 100 000 and rate ratios per 100 000 (IRR) were reported for age, sex, race, and ethnicity for each pathological subtype with 95% confidence intervals (95% CI). Using CDC's National Program of Cancer Registries survival database, survival curves and hazard ratios (HRs) evaluated overall survival from 2001 to 2016.</p><p><strong>Results: </strong>CPP had the highest overall incidence (AAIR: 0.034, 95% CI: 0.033-0.036), followed by CPC (AAIR: 0.008, 95% CI: 0.008-0.009) and aCPP (AAIR: 0.005, 95% CI: 0.005-0.006). Incidence was highest among children less than one year old among all subtypes (CPP AAIR: 0.278; aCPP AAIR: 0.140; CPC AAIR: 0.195), reducing as patients aged. Overall survival was worse among patients with CPC, being five times more likely to die compared to patients with CPP (HR: 5.23, 95% CI: 4.05-7.54, <i>P</i> < .001).</p><p><strong>Conclusions: </strong>This analysis is the most current and comprehensive study in the US on the incidence and survival for CPT. Population based statistics provide critical information in understanding disease characteristics, which impact patient care and prognosis.</p>","PeriodicalId":19234,"journal":{"name":"Neuro-oncology practice","volume":"10 1","pages":"41-49"},"PeriodicalIF":2.4000,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9837781/pdf/npac062.pdf","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuro-oncology practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/nop/npac062","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 1

Abstract

Background: There are limited data available on incidence and survival of patients with choroid plexus tumors (CPT). This study provides the most current epidemiological analysis of choroid plexus tumors from 2004 to 2017 in the United States.

Methods: Data on 2013 patients with CPT were acquired from the Central Brain Tumor Registry of the United States in collaboration with the Centers for Disease Control and Prevention (CDC) and the National Cancer Institute, from 2004 to 2017. CPT cases were classified by the following pathological subtypes: choroid plexus papilloma (CPP), atypical choroid plexus papilloma (aCPP), and choroid plexus carcinoma (CPC). Frequencies and age-adjusted incidence rates (AAIR) per 100 000 and rate ratios per 100 000 (IRR) were reported for age, sex, race, and ethnicity for each pathological subtype with 95% confidence intervals (95% CI). Using CDC's National Program of Cancer Registries survival database, survival curves and hazard ratios (HRs) evaluated overall survival from 2001 to 2016.

Results: CPP had the highest overall incidence (AAIR: 0.034, 95% CI: 0.033-0.036), followed by CPC (AAIR: 0.008, 95% CI: 0.008-0.009) and aCPP (AAIR: 0.005, 95% CI: 0.005-0.006). Incidence was highest among children less than one year old among all subtypes (CPP AAIR: 0.278; aCPP AAIR: 0.140; CPC AAIR: 0.195), reducing as patients aged. Overall survival was worse among patients with CPC, being five times more likely to die compared to patients with CPP (HR: 5.23, 95% CI: 4.05-7.54, P < .001).

Conclusions: This analysis is the most current and comprehensive study in the US on the incidence and survival for CPT. Population based statistics provide critical information in understanding disease characteristics, which impact patient care and prognosis.

脉络膜丛肿瘤在美国的发病率和生存率。
背景:关于脉络膜丛肿瘤(CPT)患者的发病率和生存率的数据有限。本研究提供了2004年至2017年美国脉络膜丛肿瘤的最新流行病学分析。方法:从2004年至2017年,与疾病控制与预防中心(CDC)和国家癌症研究所合作,从美国中央脑肿瘤登记处获得2013例CPT患者的数据。CPT病例按病理亚型分为:脉络膜丛乳头状瘤(CPP)、非典型脉络膜丛乳头状瘤(aCPP)和脉络膜丛癌(CPC)。报告了每种病理亚型的年龄、性别、种族和民族的频率和每10万人的年龄调整发病率(AAIR)以及每10万人的发病率比(IRR),可信区间为95% (95% CI)。使用疾病预防控制中心的国家癌症登记处生存数据库,生存曲线和风险比(hr)评估了2001年至2016年的总生存率。结果:CPP的总发病率最高(AAIR: 0.034, 95% CI: 0.033-0.036),其次是CPC (AAIR: 0.008, 95% CI: 0.008-0.009)和aCPP (AAIR: 0.005, 95% CI: 0.005-0.006)。在所有亚型中,1岁以下儿童的发病率最高(CPP AAIR: 0.278;aCPP AAIR: 0.140;CPC AAIR: 0.195),随着患者年龄的增长而降低。CPC患者的总生存率较差,死亡的可能性是CPP患者的5倍(HR: 5.23, 95% CI: 4.05-7.54, P)结论:该分析是美国关于CPT发病率和生存率的最新、最全面的研究。以人口为基础的统计提供了了解疾病特征的关键信息,这些特征影响患者的护理和预后。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Neuro-oncology practice
Neuro-oncology practice CLINICAL NEUROLOGY-
CiteScore
5.30
自引率
11.10%
发文量
92
期刊介绍: Neuro-Oncology Practice focuses on the clinical aspects of the subspecialty for practicing clinicians and healthcare specialists from a variety of disciplines including physicians, nurses, physical/occupational therapists, neuropsychologists, and palliative care specialists, who have focused their careers on clinical patient care and who want to apply the latest treatment advances to their practice. These include: Applying new trial results to improve standards of patient care Translating scientific advances such as tumor molecular profiling and advanced imaging into clinical treatment decision making and personalized brain tumor therapies Raising awareness of basic, translational and clinical research in areas of symptom management, survivorship, neurocognitive function, end of life issues and caregiving
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信